**Small activating ribonucleic acid reverses tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant lung cancer by increasing the expression of phosphatase and tensin homolog**

Meng Li, Zhongmin Peng, Wangang Ren & Zhou Wang

Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, China

**Keywords**
Epidermal growth factor receptor; non-small cell lung cancer; phosphatase and tensin homolog; ribonucleic acid activation; tyrosine kinase inhibitors.

**Correspondence**
Zhou Wang, Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan 250021, China. Tel: +86 531 8793 8911 Email: wz620226@hotmail.com

Received: 25 March 2016; Accepted: 3 April 2016.

doi: 10.1111/1759-7714.12356

Thoracic Cancer 7 (2016) 481–485

**Abstract**

**Background:** Epidermal growth factor receptor-tyrosine kinase inhibitors (TKI-EGFRs) present a new prospect for the treatment of lung cancer. However, in clinical application, the majority of patients become TKI resistant within a year. More and more studies have shown that a loss of phosphatase and tensin homolog (PTEN) expression is associated with TKI resistance. An alternative method of upregulating PTEN expression may reverse TKI resistance.

**Methods:** We designed five candidate small activating ribonucleic acids (saRNAs) to target PTEN, and transfected them into H-157 cells to screen out functional saRNA. We used reverse transcriptase-polymerase chain reaction and Western blot to evaluate the effect of saRNA to PTEN expression. We then analyzed the growth and apoptosis of cells transfected with saRNA under the treatment of TKI to investigate whether saRNAs can reverse TKI resistance by upregulating PTEN expression.

**Results:** The functional saRNA we designed could upregulate PTEN expression. The H-157 cells transfected with saRNA grew slower in the presence of TKI drugs than the cells that were not transfected with saRNA. The apoptosis rate was also obviously higher.

**Conclusions:** Our study proves that loss of PTEN expression is an important mechanism of TKI resistance. It is possible to control TKI resistance by upregulating PTEN expression using RNA activation technology.

**Introduction**

Today, lung cancer has the highest fatality rate in the world. Because most patients are already in advanced stage at diagnosis, only a minority are eligible for surgery. Seventy percent of patients have no choice but to accept chemotherapy and radiotherapy, which is only effective in 25% of cases. Therefore, a new treatment option is needed.

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) present a new prospect for the treatment of lung cancer. In patients with sensitive EGFR gene mutations, TKIs achieve an objective response rate of 70%. As TKIs are also only associated with minor side effects, they have taken the place of traditional chemotherapy as the first line treatment for lung cancer with EGFR mutations. However, in clinical application, the majority of patients become TKI resistant within a year. The key to resolving this issue is to clarify the mechanism of TKI resistance and find a way to reverse it. Several factors have been identified as contributors to resistance, including Kirsten rat sarcoma oncogene homolog mutation, secondary EGFR mutation, mesenchymal-epithelial transition amplification, and overexpression of hepatocyte growth factor. Research has also determined that a loss of phosphatase and tensin homolog (PTEN) is also associated with TKI resistance.

The inactivation or deletion of PTEN occurs in many kinds of tumors, including non-small cell lung cancer.
saRNA reverses TKI resistance

M. Li et al.

(NSCLC). Recent studies have shown that a loss of PTEN causes continuous activation of protein kinase B (Akt), which is critical in the phosphoinositide 3-kinase (PI3K)-Akt pathway that leads to cell proliferation.9–11 When NSCLC with low PTEN expression is treated with TKIs, resistance will occur.12 Therefore, TKI resistance could be reversed by upregulating PTEN expression levels.

In this study, we attempt to upregulate PTEN expression by ribonucleic acid activation (RNAa), an emerging technology that can activate specific genes simply, efficiently, and consistently in an H-157 lung cancer cell line, in order to illuminate the role of PTEN in TKI resistance and find a method to reverse such resistance.

Methods

Cell culture and reagents

H-157 cells obtained from Shanghai Yanneng Biology Company were cultured in RPMI1640 supplemented with 10% fetal bovine serum and 100 IU/mL penicillin under a humidified atmosphere of 5% CO2 at 37°C. Gefitinib was provided by AstraZeneca (Cheshire, United Kingdom).

Design and screening of small activating ribonucleic acid (saRNA)

Following the guidelines provided by existing literature and using Ambion software (http://www.ambion.com/tech-lib/misc/siRNA_finder.html), we designed five pairs of small double-stranded RNAs (dsRNA) that could activate the PTEN gene.13,14 We used dsRNA non-homologous to the whole human genome as the control small activating ribonucleic acid (saRNA; Table 1). All dsRNAs were synthesized by Shanghai Sangon Biotech Company. dsRNAs were transfected into H-157 cell lines. PTEN expression was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). We defined the functional saRNA as a dsRNA that could double the expression of the target gene.

Transfection of saRNA into cells

We divided the H-157 cells into three groups. The saRNA group was transfected with functional saRNA, the control group was transfected with dsControl, and the mock group required no processing. Before saRNA transfection, cells were treated with trypsin and seeded into six-well plates at a density of 40–50% and cultured without antibiotics. saRNAs were then transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at a concentration of 50 nM/L according to the manufacturer’s instructions. The cells were then incubated for 72 hours.

Reverse transcriptase-polymerase chain reaction for phosphatase and tensin homolog expression (PTEN)

We analyzed PTEN expression for RNA by RT-PCR. Total RNA was extracted from H-157 cells with Trizol reagent (Invitrogen) following the manufacturer’s instructions. PTEN messenger (m)RNA was detected using RT (MBI Fermentas, Amherst, MA USA). The primer for PTEN was (Invitrogen, Carlsbad, CA, USA) at a concentration of 50 nM/L according to the manufacturer’s instructions. The gel images were acquired using Imagemaster VDS-CL (Amersham, Uppsala, Sweden) to perform comparative analysis with Bandleader 3.0 software (Magnite Ltd., Tel Aviv, Israel). We calculated the densitometry ratio of PTEN to glyceraldehyde 3-phosphate dehydrogenase to obtain the relative expression intensity.

Western blot for PTEN expression

Western blot was used to examine PTEN protein expression. Cells were washed with ice-cold phosphate buffered saline (PBS) and then lysed in Triton X-100 buffer

Table 1 Sequence of candidate and control saRNA

| saRNA     | Sequence                                                                 |
|-----------|--------------------------------------------------------------------------|
| dpPTEN-1067 | Forward: 5'-GACAGAGACAUAAUUUA[dt][dt]-3'                                |
|           | Reverse: 5'-UAATTCGUCUCUGUC[dt][dt]-3'                                   |
| dpPTEN-864  | Forward: 5'-GACGGUGUAUCAUGUA[dt][dt]-3'                                  |
|           | Reverse: 5'-GGCAUUUGUUGCUAGCC[dt][dt]-3'                                 |
| dpPTEN-833  | Forward: 5'-UGCGCGUGUGUGUGUGA[dt][dt]-3'                                 |
|           | Reverse: 5'-UCUACAAACACCCACCA[dt][dt]-3'                                 |
| dpPTEN-781  | Forward: 5'-UCUUAGGAAAAGCUGUA[dt][dt]-3'                                 |
|           | Reverse: 5'-UGAAGGCGUUCCUUJCAGU[dt][dt]-3'                               |
| dpPTEN-577  | Forward: 5'-GUCUCACUGUGUACACCGA[dt][dt]-3'                               |
|           | Reverse: 5'-UCAAGGUAACACAGUGAC[dt][dt]-3'                                |
| dpControl  | Forward: 5'-ACUCAUGAGUCACUC[dt][dt]-3'                                   |
|           | Reverse: 5'-UCACUCAGUACCGUGU[dt][dt]-3'                                  |

ds, double strand; PTEN, phosphatase and tensin homolog.

Table 2 Reverse transcriptase-polymerase chain reaction primers

| Gene     | Primer sequence                                                                 |
|----------|--------------------------------------------------------------------------------|
| PTEN     | Forward: 5'-ATATTCTCAGAAAAAGCTGG-3'                                           |
|          | Reverse: 5'-TTATTAGGTAAAGGACTAA-3'                                           |
| GAPDH    | Forward: 5'-CACCATGAGAAAGCCGKGGG-3'                                           |
|          | Reverse: 5'-GACGGCACACCTGKGGGTAG-3'                                          |

GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PTEN, phosphatase and tensin homolog.
(50 mmol/L 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid, 150 mmol/L sodium chloride, 50 mmol/L sodium fluoride, 1% Triton X-100, and 10% glycerol containing 1 mmol/L ethylenediaminetetraacetic acid, 1 mmol/L phenylmethylsulfonyl fluoride, 10 μg/mL aprotonin, 1 μg/mL leupeptin, and 1 mmol/L sodium orthovanadate). Cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to membranes. The membranes were first incubated with primary antibodies specific for either PTEN or β-actin. The membranes were then incubated with corresponding peroxidase-conjugated secondary antibodies. The signal was detected with an electrochemiluminescence kit (Amersham Biosciences, Buckinghamshire, UK).

Cell-growth assay

H-157 cells were seeded in 96-well plates at 50 000 cells/well. One day later, cells were placed in fresh media containing gefitinib at a concentration of 1 μmol/L and cultured for seven days. We then harvested cells by trypsinization and counted the cell number using a Coulter counter. We counted three wells of cells every day and took an average. A cell growth curve was plotted using culture time and cell number.

Detection of cell apoptosis

Cells in the logarithmic growth phase were plated in six-well plates. After suspension for 24 hours for attachment, cells were washed with PBS twice and gefitinib was added at a concentration of 1 μmol/L. After 48 hours, the cells were harvested. The cells were then trypsinized, counted, washed with cold PBS, and incubated with propidium iodide and annexin V at room temperature in the dark for 15 minutes. Cells were detected by flow cytometry.

Statistical analysis

Results were analyzed with SPSS version 19.0 (IBM Corp., Armonk, NY, USA). Data were given as the mean ± standard deviation. Variance analysis was used for comparisons of multiple groups. P < 0.05 was considered statistically significant.

Results

Screening of functional saRNA

We synthesized five pairs of candidate saRNAs and transfected them into the H-157 cells. We then analyzed the effect of saRNA on PTEN expression by RT-PCR. Three of the five pairs of candidate saRNA could upregulate PTEN expression. dsPTEN-1067 can enhance PTEN expression more than twice (Fig 1 and Table 3).

Table 3 Effect of saRNA to PTEN expression by RT-PCR

| saRNA     | Relative intensity of PTEN expression |
|-----------|--------------------------------------|
| dsPTEN-1067 | 0.69                                  |
| dsPTEN-864  | 0.61                                  |
| dsPTEN-833  | 0.29                                  |
| dsPTEN-781  | 0.43                                  |
| dsPTEN-577  | 0.22                                  |
| dsControl   | 0.27                                  |
| Mock        | 0.31                                  |

PTEN, phosphatase and tensin homolog; RT-PCR, reverse transcriptase-polymerase chain reaction.

Effect of saRNA on PTEN expression by Western blot

The functional saRNA dsPTEN-1067 we had sifted out was transfected into the H-157 cells. Western blot was then used to analyze the saRNA influence on PTEN protein expression. The results are shown in Figure 2. After transfection with functional saRNA, PTEN expression in the H-157 cells was obviously enhanced.
Cell growth curve of gefitinib treated H-157 cell after saRNA transfection

As shown in Figure 3, when treated with gefitinib, H-157 cells transfected with functional saRNA grew more slowly than the cells that were not transfected and those transfected with the control saRNA (F = 23.11, P < 0.05). This result may suggest that reconstruction of PTEN expression will restore the cell’s sensitivity to TKI.

saRNA increased gefitinib-induced apoptosis

After gefitinib treatment, the apoptosis rate of H-157 cells that were not transfected with saRNA was 0.33 ± 0.14%. The apoptosis rate of H-157 cells transfected with the dsControl was 1.74 ± 0.17%. After transfection with functional saRNA, the apoptosis rate of the H-157 cells increased to 17.82 ± 2.37% (F = 32.06, P < 0.05). This result illustrates that saRNA can promote apoptosis by upregulating PTEN expression when treated with gefitinib (Fig 4).

Discussion

Recently, more and more studies have suggested that PTEN expression dysfunction contributes to TKI resistance in NSCLC patients. PTEN is an important tumor suppressor gene, which can inhibit tumor proliferation by inhibiting P13K/Akt pathway activation.9–11 PTEN is a common node of multiple signal pathways. If the gene mutates or has lower expression, its tumor suppressor function will be lost. Bidkhori et al. found that in NSCLC cells with a loss of PTEN expression, erlotinib is unable to downregulate levels of phosphorylated Akt, which is why cancer cells become resistant to TKI.15 Yamamoto et al. and Sos et al. also support this conclusion, determining that in NSCLC cells with EGFR mutation, Akt activation contributes to TKI resistance; continuous Akt activation is caused by low PTEN expression.16,17 Zhuang et al. increased the PTEN expression level in H-157 cells using X-ray irradiation in vitro and found that the cells became more sensitive to TKI.18 Maeda et al. transfected pIRES-PTEN into NSCLC cells to temporarily upregulate PTEN expression.19 Twenty-four hours later, after successful transfection, they found that PTEN upregulation inhibited Akt activation and TKI sensitivity was restored. Thus, if PTEN expression can be reconstructed, TKI resistance may be controlled.

To date no technology that can simply and consistently activate PTEN expression exists. RNA activation is an emerging technology, which can easily activate target genes with a long-term effect.20 There is no need to build a vector or transf ect into new genes. This technology is more suitable for disease treatment than transgenic technology. Our study has utilized this promising technology to reverse TKI resistance.

The H-157 cell is an NSCLC cell with low PTEN expression that provided us with a research basis.21 We designed five candidate saRNAs to target the PTEN gene.
these saRNAs can upregulate mRNA PTEN expression. We chose an saRNA that could upregulate PTEN mRNA expression more than twice as a functional saRNA. This functional RNA can also activate PTEN protein expression. This result suggests that RNAa technology is suitable for lung cancer treatment.

After successful transfection of functional saRNA into H-157 cells, we analyzed the growth and apoptosis of H-157 cells under TKI treatment. We found that cells transfected with saRNA grew slower in the presence of TKI drugs than the cells that were not transfected with saRNA. The apoptosis rate was also obviously higher. This result may be related to the inhibition of Akt activation caused by PTEN upregulation.

Our study proves that loss of PTEN expression is an important mechanism of TKI resistance. It is possible to control TKI resistance by upregulating PTEN expression. We have demonstrated a new method of reversing TKI resistance using RNAa technology. However, we only tested this method in vitro, thus, further study using in vivo tests are required. It is also important to design a more efficient saRNA. We look forward to the prospect of RNAa technology in the development of new target drugs.

**Disclosure**

No authors report any conflict of interest.

**Reference**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. (Published erratum appears in CA Cancer J Clin 2011; 61: 134.) CA Cancer J Clin 2011; 61: 69–90.

2. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systemic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617–25.

3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.

4. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8.

5. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8.

6. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169–81.

7. Wu YL, Sun Y, Liao ML et al. [The processing of epidermal growth factor receptor mutation lung cancer.] Xun Zheng Yi Xue 2011; 11: 65–8. (In Chinese.)

8. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895–9.

9. Gupta A, Yang Q, Pandita RK et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009; 8: 2198–210.

10. Mahmainathan L, Choudhury GG. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 2004; 279: 15258–68.

11. Silva A, Yunes JA, Cardoso BA et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762–74.

12. Okamoto K, Okamoto I, Hatashita E et al. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin. Mol Cancer Ther 2012; 11: 204–13.

13. Huang V, Qin Y, Wang J et al. RNAa is conserved in mammalian cells. PLoS One 2010; 5 (1): e8848.

14. Li LC, Okino ST, Zhao H et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 2006; 103: 17337–42.

15. Bidkhor G, Moeini A, Masoudi-Nejad A. Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression. PLoS One 2012; 7 (10): e48004.

16. Yamamoto C, Basaki Y, Kawahara A et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 8715–25.

17. Sos ML, Koker M, Weir BA et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69: 3256–61.

18. Zhuang HQ, Wang J, Yuan ZY, Zhao LJ, Wang P, Wang CL. The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. J Exp Clin Cancer Res 2009; 28: 123.

19. Maeda M, Murakami Y, Watariki K, Kwire M, Izumi H, Ono M. Cpg hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines. Lung Cancer 2015; 87: 625–71.

20. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 2007; 3: 166–73.

21. Bianco R, Shin I, Ritter CA et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the